A systematic review of the use of rituximab as induction therapy in renal transplantation

Tedder, 1986, Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes, Eur J Immunol, 16, 881, 10.1002/eji.1830160802 Genberg, 2006, Pharmacodynamics of rituximab in kidney allotransplantation, Am J Transplant, 6, 2418, 10.1111/j.1600-6143.2006.01497.x Sidner, 2004, In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody, Hum Antibodies, 13, 55, 10.3233/HAB-2004-13301 Kopchaliiska, 2009, Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients, Transplantation, 87, 1394, 10.1097/TP.0b013e3181a27683 Zarkhin, 2011, Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients, Transplantation, 91, 1010, 10.1097/TP.0b013e318213df29 Stroopinsky, 2012, Rituximab-induced direct inhibition of T-cell activation, Cancer Immunol Immunother, 61, 1233, 10.1007/s00262-011-1168-2 Maloney, 1997, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood, 90, 2188, 10.1182/blood.V90.6.2188 De Vita, 2002, Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells, Arthritis Rheum, 46, 2029, 10.1002/art.10467 Kneitz, 2002, Effective B cell depletion with rituximab in the treatment of autoimmune diseases, Immunobiology, 206, 519, 10.1078/0171-2985-00200 Evans, 1985, The quality of life of patients with end-stage renal disease, N Engl J Med, 312, 553, 10.1056/NEJM198502283120905 Port, 1993, Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients, JAMA, 270, 1339, 10.1001/jama.1993.03510110079036 Russell, 1992, The quality of life in renal transplantation—a prospective study, Transplantation, 54, 656, 10.1097/00007890-199210000-00018 Hawksworth, 2009, New directions for induction immunosuppression strategy in solid organ transplantation, Am J Surg, 197, 515, 10.1016/j.amjsurg.2008.04.025 Szczech, 1997, Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis, J Am Soc Nephrol, 8, 1771, 10.1681/ASN.V8111771 Webster, 2010, Interleukin 2 receptor antagonists for kidney transplant recipients, Cochrane Database Syst Rev, 1, CD003897 Morgan, 2012, Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis, Transplantation, 93, 1179, 10.1097/TP.0b013e318257ad41 Morris, 1968, Serotyping for homotransplantation. XII. Occurrence of cytotoxic antibodies following kidney transplantation in man, Transplantation, 6, 392, 10.1097/00007890-196805000-00010 Morris, 1969, Serotyping for homotransplantation. XXII. Specificity of cytotoxic antibodies developing after renal transplantation, Br Med J, 1, 758, 10.1136/bmj.1.5646.758 Terasaki, 2004, Predicting kidney graft failure by HLA antibodies: a prospective trial, Am J Transplant, 4, 438, 10.1111/j.1600-6143.2004.00360.x Gaston, 2010, Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure, Transplantation, 90, 68, 10.1097/TP.0b013e3181e065de Macklin, 2014, A systematic review of the use of rituximab for desensitization in renal transplantation, Transplantation, 98, 794, 10.1097/TP.0000000000000362 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ, 339, b2535, 10.1136/bmj.b2535 Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4 Howick Tydén, 2009, A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation, Transplantation, 87, 1325, 10.1097/TP.0b013e3181a235fd Tydén, 2008, A prospective, randomised, placebo controlled, multicenter study of the efficacy and safety of rituximab as induction therapy together with tacrolimus, mycophenolate mofetil and steroids in renal transplantation abstract, Transplantation, 86, 300, 10.1097/01.tp.0000331956.57287.df van den Hoogen, 2013, Rituximab to prevent renal allograft rejection; a randomized, double-blind, placebo-controlled trial, Am J Transplant, 13, 112 van den Hoogen, 2010, Safety of rituximab as induction therapy in renal transplantation; results of an interim analysis, Transplantation, 90, 64, 10.1097/00007890-201007272-00122 Tsai, 2012, Rituximab induction therapy provided additional immunosuppressive effect and functional benefit to non-sensitized renal transplant recipients: an interim report, Am J Transplant, 12, 319 Clatworthy, 2009, B cell depleting induction therapy increases acute cellular rejection in renal transplantation, Am J Transplant, 9, 283 Sundberg, 2009, A pilot study of campath-1H and rituximab induction therapy combined with cellcept to allow for a calcineurin inhibitor-free regimen after renal transplantation, Am J Transplant, 9, 258 Tydén, 2012, A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up, Transplantation, 94, e21, 10.1097/01.tp.0000418580.88642.e1 Tydén, 2010, Authors' reply to letter by van den Hoogen and Hilbrands, Transplantation, 89, 1295, 10.1097/TP.0b013e3181d368de van den Hoogen, 2009, More on B-cell-depleting induction therapy and acute cellular rejection, N Engl J Med, 361, 1215 Clatworthy, 2009, B-cell-depleting induction therapy and acute cellular rejection, N Engl J Med, 360, 2683, 10.1056/NEJMc0808481 Joosten, 2014, Anti-B cell therapy with rituximab as induction therapy in renal transplantation, Transpl Immunol, 31, 207, 10.1016/j.trim.2014.09.011 Genberg, 2008, ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up, Transplantation, 85, 1745, 10.1097/TP.0b013e3181726849 Kyaw, 2011, B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions, Circ Res, 109, 830, 10.1161/CIRCRESAHA.111.248542 Garypidou, 2004, Cardiac toxicity during rituximab administration, Leuk Lymphoma, 45, 203, 10.1080/10428190310001607160 Armitage, 2008, Acute coronary syndromes complicating the first infusion of rituximab, Clin Lymphoma Myeloma, 8, 253, 10.3816/CLM.2008.n.035 Kilickap, 2008, Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma, Med Oncol, 25, 437, 10.1007/s12032-008-9062-2 Emery, 2010, Ann Rheum Dis, 69, 1629, 10.1136/ard.2009.119933 Vincenti, 1998, Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group, N Engl J Med, 338, 161, 10.1056/NEJM199801153380304 Agarwal, 2004, Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses, Am J Transplant, 4, 1357, 10.1111/j.1600-6143.2004.00502.x Neta, 1974, Specific suppression of delayed hypersensitivity: the possible presence of a suppressor B cell in the regulation of delayed hypersensitivity, J Immunol, 113, 1716, 10.4049/jimmunol.113.6.1716 Matsushita, 2008, Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression, J Clin Invest, 118, 3420 Mizoguchi, 2000, Regulatory role of mature B cells in a murine model of inflammatory bowel disease, Int Immunol, 12, 597, 10.1093/intimm/12.5.597 Fillatreau, 2002, B cells regulate autoimmunity by provision of IL-10, Nat Immunol, 3, 944, 10.1038/ni833 Hadley, 2014, Nonvasculitic autoimmune meningoencephalitis after rituximab: the potential downside of depleting regulatory B cells in the brain, J Clin Rheumatol, 20, 163, 10.1097/RHU.0000000000000099 Jackson, 2014, A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation, Kidney Int Pallier, 2010, Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype, Kidney Int, 78, 503, 10.1038/ki.2010.162 Newell, 2010, Identification of a B cell signature associated with renal transplant tolerance in humans, J Clin Invest, 120, 1836, 10.1172/JCI39933 Viklicky, 2013, B-cell-related biomarkers of tolerance are up-regulated in rejection-free kidney transplant recipients, Transplantation, 95, 148, 10.1097/TP.0b013e3182789a24 Thompson, 2010, B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis, J Clin Immunol, 30, 99, 10.1007/s10875-009-9327-3 Cherukuri, 2012, An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation, Am J Transplant, 12, 919, 10.1111/j.1600-6143.2011.03891.x Heidt, 2012, B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naive B cells, Am J Transplant, 12, 1784, 10.1111/j.1600-6143.2012.04012.x